BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22661897)

  • 1. Critical evaluation of the efficacy and tolerability of azilsartan.
    De Caterina AR; Harper AR; Cuculi F
    Vasc Health Risk Manag; 2012; 8():299-305. PubMed ID: 22661897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension.
    Hjermitslev M; Grimm DG; Wehland M; Simonsen U; Krüger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):225-233. PubMed ID: 28444983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azilsartan: Novel Angiotensin Receptor Blocker.
    Dargad RR; Parekh JD; Dargad RR; Kukrety S
    J Assoc Physicians India; 2016 Mar; 64(3):96-98. PubMed ID: 27731574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azilsartan medoxomil for the treatment of hypertension.
    Vasiliou S
    Drugs Today (Barc); 2011 Sep; 47(9):647-51. PubMed ID: 21971539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azilsartan medoxomil: a review of its use in hypertension.
    Perry CM
    Clin Drug Investig; 2012 Sep; 32(9):621-39. PubMed ID: 22877322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
    Dudkowski C; Karim A; Zhao Z; Alonso AB; Garg D; Preston RA
    J Clin Pharmacol; 2018 Jan; 58(1):48-56. PubMed ID: 28750149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
    Angeli F; Verdecchia P; Pascucci C; Poltronieri C; Reboldi G
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):379-85. PubMed ID: 23387516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension.
    Kamada T; Hayashi M; Fujiwara W; Yoshikawa D; Mukaide D; Sugishita Y; Yoshinaga M; Itoh T; Yokoi H; Ishii J; Watanabe E; Ozaki Y; Izawa H
    Drug Chem Toxicol; 2017 Jan; 40(1):110-114. PubMed ID: 27424785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
    Weber MA; White WB; Sica D; Bakris GL; Cao C; Roberts A; Kupfer S
    Blood Press Monit; 2014 Apr; 19(2):90-7. PubMed ID: 24445723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
    Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
    Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker?
    Barrios V; Escobar C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2249-61. PubMed ID: 24070321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.
    Baker WL; White WB
    Ann Pharmacother; 2011 Dec; 45(12):1506-15. PubMed ID: 22116996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry.
    Gitt AK; Bramlage P; Potthoff SA; Baumgart P; Mahfoud F; Buhck H; Ehmen M; Ouarrak T; Senges J; Schmieder RE;
    BMC Cardiovasc Disord; 2016 Mar; 16():56. PubMed ID: 26956148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Azilsartan Medoxomil Capabilities in Arterial Hypertension and Obesity].
    Vasyuk YA; Shupenina EY; Nesvetov VV; Nesterova EA; Golubkova EI
    Kardiologiia; 2016 Dec; 56(11):108-112. PubMed ID: 28290827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azilsartan medoxomil/chlorthalidone: a new fixed-dose combination antihypertensive.
    Pierini D; Anderson KV
    Ann Pharmacother; 2013 May; 47(5):694-703. PubMed ID: 23585646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Azilsartan: a new angiotensin receptor blocker].
    Rakugi H; Enya K
    Nihon Rinsho; 2012 Sep; 70(9):1615-20. PubMed ID: 23012812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
    Bakris GL; Sica D; White WB; Cushman WC; Weber MA; Handley A; Song E; Kupfer S
    Am J Med; 2012 Dec; 125(12):1229.e1-1229.e10. PubMed ID: 22939358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.